Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2017 | Key findings of the Endeavour study

Evangelos Terpos • 21 Apr 2017
COMy 2017
Multiple Myeloma Bortezomib Carfilzomib Dexamethasone

Evangelos Terpos, MD, PhD, from the University of Athens, School of Medicine, Athens, Greece, discusses the Endeavour study (NCT01568866) at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. This study compared the progression free survival of dexathasone combined with bortezomib or carfilzomib. The key finding of this study was that dexamethasone plus carfilzomib produced an overall survival advantage, in comparison to dexamethasone plus botezomib.

More from Evangelos Terpos

Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing 2:38
Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing
Evangelos Terpos • 12 May 2025
Advice for managing bone disease in multiple myeloma 3:25
Advice for managing bone disease in multiple myeloma
Evangelos Terpos • 12 May 2025
The potential of sustained MRD negativity to guide maintenance discontinuation post-SCT in myeloma 3:34
The potential of sustained MRD negativity to guide maintenance discontinuation post-SCT in myeloma
Evangelos Terpos • 12 May 2025
Isa-VCd followed by isa + len maintenance in newly diagnosed myeloma with severe renal impairment 0:57
Isa-VCd followed by isa + len maintenance in newly diagnosed myeloma with severe renal impairment
Evangelos Terpos • 6 Dec 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals